Cullinan Therapeutics, Inc. Common Stock
CGEMCullinan Therapeutics, Inc. (CGEM) is a biotechnology company focused on developing gene editing and gene therapy technologies to treat genetic and chronic diseases. The company aims to leverage advanced research platforms to create innovative therapeutic solutions with a focus on precision medicine.
Company News
Cullinan Therapeutics announced positive Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefit including remissions in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following single target doses. The drug demonstrated deep, dose-dependent B cell depletion with a favorable safety pr...
Cullinan Therapeutics announced that initial clinical data from Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, will be presented at EULAR 2026 Congress in June. The data shows favorable safety profiles, robust B cell depletion, and early promising clinical activity in patients with treatment-refractory rheumatoid arthritis and systemic lu...
Cullinan Therapeutics presented preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, demonstrating potential for B cell depletion across multiple autoimmune diseases like rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus.
Cullinan Therapeutics will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum, presenting insights into their clinical-stage therapeutic assets targeting autoimmune diseases and cancer.
Cullinan Therapeutics announced ongoing clinical trials for CLN-978 and velinotamig in autoimmune diseases, shared zipalertinib oncology results, and appointed two new board members while maintaining a strong cash position of $510.9 million.
